Rituximab [Truxima®]

[SDL] Rituximab Biosimilar (Truxima) Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

[MSHL] Rituximab biosimilar Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

1. For cancer treatment.

[MSHL] Rituximab Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Ibrutinib in combination with rituximab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).

2. Ibrutinib in combination with rituximab, for the treatment of Waldenstrom’s Macroglobulinaemia.

[MSHL] Rituximab biosimilar Concentrate For Solution For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Venetoclax in combination with rituximab biosimilar (subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months.

[MSHL] Rituximab biosimilar Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Polatuzumab in combination with rituximab biosimilar (subsidised brand), cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL) in patients with an international prognostic index (IPI) score of 3 to 5.

[MSHL] Rituximab Concentrate For Infusion 100 mg/10 mL, 500 mg/50 mL

1. Polatuzumab in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone for previously untreated diffuse large B-cell lymphoma (DLBCL).

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

13/09/2024 Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions

The Ministry of Health’s Drug Advisory Committee has reviewed all available treatments for cancer to update the MOH List of Subsidised Drugs in line with local clinical practice and medical advancements. As part of this review, Technology Guidances have been prepared which describe the subsidy recommendations for many cancer drugs for specific clinical conditions. The remaining treatments which have been considered by the Committee are included in this document.

[R] Based on the available evidence, the Ministry of Health’s Drug Advisory Committee has recommended:

• Abemaciclib 50 mg, 100 mg and 150 mg tablets;

• Abiraterone acetate 250 mg tablets;

• Afatinib 20 mg, 30 mg and 40 mg tablets;

• Alectinib 150 mg capsule;

• Anagrelide 0.5 mg capsule;

• Atezolizumab 840 mg/14 mL and 1200 mg/20 mL concentrate for solution for infusion;

• Avelumab 200 mg/10 mL concentrate for solution for infusion;

• Axitinib 1 mg and 5 mg tablets;

• Azacitidine 100 mg injection;

• Bendamustine 25 mg and 100 mg concentrate for infusion;

• Bicalutamide 50 mg tablet;

• Bortezomib 3.5 mg injection;

• Brentuximab vedotin 50 mg powder for concentrate for solution for infusion;

• Brigatinib 30 mg, 90 mg and 180 mg tablets;

• Cabozantinib 20 mg, 40 mg and 60 mg tablets;

• Ceritinib 150 mg capsule;

• Cetuximab 100 mg/20 mL solution for infusion;

• Cisplatin 100 mg/100 mL concentrate for infusion;

• Cyproterone 50 mg tablet;

• Dabrafenib 50 mg and 75 mg capsules;

• Dasatinib 20 mg, 50 mg and 70 mg tablets;

• Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion;

• Epirubicin 50 mg/25 mL injection;

• Eribulin mesylate 1 mg/2 mL solution for injection;

• Erlotinib 100 mg and 150 mg tablets;

• Exemestane 25 mg tablet;

• Fludarabine phosphate 50 mg injection;

• Fulvestrant 250 mg/5 mL solution for injection;

• Gefitinib 250 mg tablet;

• Gilteritinib fumarate 40 mg tablet;

• Goserelin 3.6 mg and 10.8 mg depot injections;

• Imatinib 100 mg and 400 mg tablets;

• Ipilimumab 50 mg/10 mL concentrate for solution for infusion;

• Lapatinib 250 mg tablets;

• Lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules;

• Leuprorelin acetate 3.75 mg and 11.25 mg depot injection;

• Lorlatinib 25 mg and 100 mg tablets;

• Megestrol 40 mg and 160 mg capsules;

• Midostaurin 25 mg capsule;

• Nilotinib 50 mg, 150 mg and 200 mg capsules;

• Nivolumab 40 mg/4 mL and 100 mg/10 mL concentrate for solution for infusion;

• Obinutuzumab 1000 mg/40 mL concentrate for solution for infusion;

• Olaparib 100 mg and 150 mg tablets;

• Oxaliplatin 200 mg/40 mL concentrate for infusion;

• Paclitaxel-albumin bound nanoparticles 100 mg injectable suspension;

• Palbociclib 75 mg, 100 mg and 125 mg capsules/tablets;

• Pazopanib 200 mg and 400 mg tablets;

• Pegylated liposomal doxorubicin 20 mg concentrate for infusion;

• Pembrolizumab 100 mg/4 mL solution for infusion;

• Pemetrexed 100 mg and 500 mg injections;

• Ponatinib 15 mg tablet;

• Ribociclib 200 mg tablet;

• Ruxolitinib 5 mg, 15 mg and 20 mg tablets;

• Somatropin 5 mg/1.5 mL and 10 mg/1.5 mL prefilled pens and solution for injection;

• Somatropin 4 mg and 5.3 mg/mL powder and solvent for solution for injection;

• Somatropin 5.83 mg/mL and 8 mg/mL solution for injection;

• Sunitinib 12.5 mg capsules;

• Trametinib 0.5 mg and 2 mg tablets; and

• Vinorelbine 50 mg/5 mL injection

for inclusion on the MOH Standard Drug List (SDL) or Medication Assistance Fund (MAF) in line with their registered indications or specific clinical criteria for treating cancer, in view of clinical need, and acceptable clinical and cost effectiveness.

[NR] Drugs that have not been recommended for subsidy are listed in the Annex.

For all drugs, the clinical indications, subsidy class, subsidy implementation dates (if applicable), and MediShield Life claim limits are provided in the Annex.

01/07/2022 Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis

The Ministry of Health’s Drug Advisory Committee has recommended:

• Baricitinib 2 mg and 4 mg tablets for treating adults with moderately to severely active rheumatoid arthritis;

• Tofacitinib 5 mg tablet for treating adults with moderately to severely active rheumatoid arthritis; and

• Rituximab biosimilar (Truxima) 500 mg concentrate for infusion for treating adults with severely active rheumatoid arthritis

in line with their registered indications.

Subsidy status

[R] Baricitinib 2 mg and 4 mg tablets and tofacitinib 5 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

[R] Baricitinib and tofacitinib should be used in line with the clinical criteria in the MAF checklist for initial and continuing prescriptions for patients with rheumatoid arthritis.

[R] Rituximab biosimilar (Truxima) 500 mg concentrate for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

[NR] SDL subsidy and MAF assistance does not apply to any formulations or strengths of tocilizumab, rituximab reference biologic (MabThera) or other rituximab biosimilars (such as Rixathon).

18/01/2021 Rituximab for treating non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

• Rituximab biosimilar (Truxima) 100 mg/10 ml and 500 mg/50 ml concentrate for infusion for treating:

  • CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma,

  • Indolent B-cell non-Hodgkin’s lymphomas,

  • Stage III-IV follicular lymphoma, or

  • CD20-positive chronic lymphocytic leukaemia

  in line with its registered indications; and

• The removal of rituximab reference biologic 100 mg/10 ml and 500 mg/50 ml concentrate for infusion (MabThera) from the Medication Assistance Fund (MAF) for all indications.

Subsidy status

[R] Truxima 100 mg/10 ml and 500 mg/50 ml concentrate for infusion is recommended for inclusion in the MOH Standard Drug List (SDL) for the abovementioned indications from 18 January 2021. The MAF listing of MabThera will cease on 19 July 2021.

[NR] SDL subsidy does not apply to any other rituximab biosimilars (such as Rixathon), or to any formulations or strengths of MabThera.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration